Potassium Chloride Injection 1g 10ml

  • Product No.: AMC14055-02
  • Specification: 1G 10ML
  • Trademark: Shinepharm
  • Support OEM/ODM: Yes
  • Mini. Order: 20000 Boxes
  • Delivery Time: 30~60 Days
  • Trade Term: FOB,CIF
  • Payment Term: T/T,L/C
  • Standard Available: CP,BP
  • Documents: GMP,COPP,CTD



For use in patients requiring supplemental potassium therapy.

Dosage and Administration:

The goal of potassium replacement therapy is to elevate the plasma concentration of the ion to within the normal range.

Dose per hour: The maximal rate of intravenous infusion is 20mmol/hour.

Dose per day: Since the normal dietary intake of potassium is 50 to 100mmol daily, it is rare that a larger amount is required during potassium replacement therapy.

Precautions & Warning:


Only use with specialist advice

ECG should be used throughout and monitored continuously

High concentrations of potassium cause serious cardiotoxicity, so the concentration of the solution should not exceed 3g (40mmol)/L and the diluted solution given slowly (maximal rate 20mmol/L)

Initially do not use with glucose infusions glucose may further decrease potassium levels

Other concurrent treatment

Extreme caution in patients on potassium sparing diuretics and other drugs that may increase potassium

Glucose infusion


Continuous ECG monitoring see above Administration

Regular potassium levels especially in patients with renal impairment

Underlying conditions

Dehydration must be corrected to ensure adequate urinary output (and potassium excretion)

Where renal excretion of potassium or cellular uptake deficient life threatening hyperkalaemia can occur with standard doses

Extreme caution with extensive tissue destruction (eg burns)

Extreme caution in cardiac disease


1.) Hypersensitivity to the active substance or to any of the excipients

2.) Sterile Potassium Chloride Injection should never be used undiluted.

3.) Hyperkalaemia (plasma-potassium concentration above 5 mmol/litre).

4.) Hyperchloraemia,

5.) Impaired renal function with oliguria, anuria or azotaemia

6.) Addison's disease,

7.) Acute dehydration

8.) Heat cramps.

Drug interactions:

Increased risk of severe hyperkalaemia with the following

• ACE-inhibitors

• Aliskerin

• Angiotensin-II receptor anatagonists

• Potassium sparing diuretics such as: amiloride, spironolactone and triamterene and aldosterone antagonists

• Ciclosporin

• Tacrolimus (not topical formulations)

Further reductions in potassium occurs with glucose infusions

Storage instructions:

Keep in outer carton. Do not store above 25°C.